Indeksnr.
|
Kemisk navn
|
EF nr.
|
CAS nr.
|
Klassificering
|
Mærkning
|
Specifikke koncentrationsgrænser, M-faktorer og ATE-værdier
|
Noter
|
Fareklasse- og kategorikode(r)
|
Faresætningskode(r)
|
Piktogram-, signalordskode(r)
|
Faresætningskode(r)
|
Suppl. faresætningskode(r)
|
»007-030-00-3
|
salpetersyre …% [C ≤ 70 %]
|
231-714-2
|
7697-37-2.
|
Ox. Liq. 3
Acute Tox. 3
Skin Corr. 1A
|
H272
H331
H314
|
GHS03
GHS06
GHS05
Dgr
|
H272
H331
H314
|
EUH071
|
Ox. Liq. 3; H272: C ≥ 65 %
inhalation: ATE = 2,65 mg/L (dampe)
Skin Corr. 1A; H314: C ≥ 20 %
Skin Corr. 1B; H314: 5 % ≤ C < 20 %
|
B«
|
»014-048-00-5
|
siliciumcarbidfibre (med en diameter på < 3 μm, en længde på > 5 μm og et højde/breddeforhold på ≥ 3:1)
|
206-991-8
|
409-21-2
308076-74-6
|
Carc. 1B
|
H350i
|
GHS08
Dgr
|
H350i«
|
|
|
|
»014-049-00-0
|
trimethoxyvinylsilan; trimethoxy(vinyl)silan
|
220-449-8
|
2768-02-7
|
Skin Sens. 1B
|
H317
|
GHS07
Wng
|
H317«
|
|
|
|
»014-050-00-6
|
tris(2-methoxyethoxy)vinylsilan;
6-(2-methoxyethoxy)-6-vinyl-2,5,7,10-tetraoxa-6-silaundecan
|
213-934-0
|
1067-53-4
|
Repr. 1B
|
H360FD
|
GHS08
Dgr
|
H360FD«
|
|
|
|
»016-098-00-3
|
dimethyldisulphid
|
210-871-0
|
624-92-0
|
Flam. Liq. 2
Acute Tox. 3
Acute Tox. 3
STOT SE 3
STOT SE 1
Eye Irrit. 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
|
H225
H331
H301
H336
H370 (øvre luftvej, inhalation)
H319
H317
H400
H410
|
GHS02
GHS06
GHS08
GHS09
Dgr
|
H225
H331
H301
H336
H370 (øvre luftvej, inhalation)
H319
H317
H410
|
|
inhalation: ATE = 5 mg/L (dampe)
oral: ATE = 190 mg/kg bw
M = 1
M = 10«
|
|
»029-024-00-X
|
granuleret kobber
[partikellængde: fra 0,9 mm til 6,0 mm; partikelbredde: fra 0,494 til 0,949 mm]
|
231-159-6
|
7440-50-8
|
Aquatic Chronic 2
|
H411
|
GHS09
|
H411«
|
|
|
|
»029-025-00-5
|
bis(N-hydroxy-N-nitrosocyclohexylaminato-O,O')kobber;
bis(N-cyclohexyl-diazenium-dioxy)-kobber;
[Cu-HDO]
|
239-703-4
|
312600-89-8
15627-09-5
|
Flam. Sol. 1
Acute Tox. 4
STOT RE 2
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
|
H228
H302
H373 (lever)
H318
H400
H410
|
GHS02
GHS07
GHS08
GHS05
GHS09
Dgr
|
H228
H302
H373(lever)
H318
H410
|
|
oral: ATE = 360 mg/kg bw
M = 1
M = 1«
|
|
»050-031-00-9
|
dioctyltindilaurat; [1]
stannan, dioctyl-, bis(coco acyloxy)-derivater [2]
|
222-883-3 [1] 293-901-5 [2]
|
3648-18-8 [1] 91648-39-4 [2]
|
Repr. 1B
STOT RE 1
|
H360D
H372 (immunsystem)
|
GHS08
Dgr
|
H360D
H372 (immunsystem)«
|
|
|
|
»601-092-00-0
|
dibenzo[def,p]chrysen;
dibenzo[a,l]pyren
|
205-886-4
|
191-30-0
|
Carc. 1B
Muta. 2
|
H350
H341
|
GHS08
Dgr
|
H350
H341
|
|
Carc. 1B; H350: C ≥ 0,001 %«
|
|
»603-237-00-3
|
ipconazol (ISO);
(1RS,2SR,5RS;1RS,2SR,5SR)-2-(4-chlorbenzyl)-5-isopropyl-1-(1H-1,2,4-triazol-1-ylmethyl)cyclopentanol
|
—
|
125225-28-7
115850-69-6
115937-89-8
|
Repr. 1B
Acute Tox. 4
STOT RE 2
Aquatic Chronic 1
|
H360D
H302
H373 (øjne, hud, lever)
H410
|
GHS08
GHS07
GHS09
Dgr
|
H360D
H302
H373 (øjne, hud, lever)
H410
|
|
oral: ATE = 500 mg/kg bw
M = 100«
|
|
»603-238-00-9
|
bis(2-(2-methoxyethoxy)ethyl)ether; tetraglym
|
205-594-7
|
143-24-8
|
Repr. 1B
|
H360FD
|
GHS08
Dgr
|
H360FD«
|
|
|
|
»603-239-00-4
|
paclobutrazol (ISO);
(2RS,3RS)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pentan-3-ol
|
—
|
76738-62-0
|
Repr. 2
Acute Tox. 4
Acute Tox. 4
Eye Irrit. 2
Aquatic Acute 1
Aquatic Chronic 1
|
H361d
H332
H302
H319
H400
H410
|
GHS08
GHS07
GHS09
Wng
|
H361d
H332
H302
H319
H410
|
|
inhalation: ATE = 3,13 mg/L (støv eller tåge)
oral: ATE = 490 mg/kg bw
M = 10
M = 10«
|
|
»603-240-00-X
|
2,2-bis(brommethyl)propan-1,3-diol
|
221-967-7
|
3296-90-0
|
Carc. 1B
Muta. 1B
|
H350
H340
|
GHS08
Dgr
|
H350
H340«
|
|
|
|
»603-241-00-5
|
geraniol;
(2E)-3,7-dimethylocta-2,6-dien-1-ol
|
203-377-1
|
106-24-1
|
Skin Sens. 1
|
H317
|
GHS07
Wng
|
H317«
|
|
|
|
»605-041-00-3
|
2-(4-tert-butylbenzyl)propionaldehyd
|
201-289-8
|
80-54-6
|
Repr. 1B
|
H360Fd
|
GHS08
Dgr
|
H360Fd«
|
|
|
|
»607-738-00-8
|
MCPA-thioethyl (ISO);
S-ethyl (4-chlor-2-methylphenoxy)ethanthioat; S-ethyl 4-chlor-o-tolyloxythioacetat
|
246-831-4
|
25319-90-8
|
Acute Tox. 4
STOT RE. 2
Aquatic Acute 1 Aquatic Chronic 1
|
H302
H373 (lever)
H400
H410
|
GHS07
GHS08
GHS09
Wng
|
H302
H373 (lever)
H410
|
|
oral: ATE = 450 mg/kg bw
M = 10
M = 10«
|
|
»607-740-00-9
|
diisooctylphthalat
|
248-523-5
|
27554-26-3
|
Repr. 1B
|
H360FD
|
GHS08
Dgr
|
H360FD«
|
|
|
|
»607-741-00-4
|
4-{[(6-chlorpyridin-3-yl)methyl](2,2-difluorethyl)amino}furan-2(5H)-on; flupyradifuron
|
—
|
951659-40-8
|
Acute Tox. 4
STOT RE 2
Aquatic Acute 1
Aquatic Chronic 1
|
H302
H373 (muskel)
H400
H410
|
GHS07
GHS08
GHS09
Wng
|
H302
H373 (muskel)
H410
|
|
oral: ATE = 500 mg/kg bw
M = 10
M = 10«
|
|
»607-742-00-X
|
thiencarbazon-methyl (ISO);
methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazol-1-yl)carbonylsulfamoyl]-5- methylthiophen-3-carboxylat
|
—
|
317815-83-1
|
Aquatic Acute 1
Aquatic Chronic 1
|
H400
H410
|
GHS09
Wng
|
H410
|
|
M = 1000
M = 1000«
|
|
»607-743-00-5
|
L-(+)-mælkesyre;
(2S)-2-hydroxypropansyre
|
201-196-2
|
79-33-4
|
Skin Corr. 1C
Eye Dam. 1
|
H314
H318
|
GHS05
Dgr
|
H314
|
EUH071«
|
|
|
»607-744-00-0
|
2-methoxyethylacrylat
|
221-499-3
|
3121-61-7
|
Flam. Liq. 3
Muta. 2
Repr. 1B
Acute Tox. 3
Acute Tox. 4
Skin Corr. 1C
Eye Dam. 1
Skin Sens. 1
|
H226
H341
H360FD
H331
H302
H314
H318
H317
|
GHS02
GHS05
GHS06
GHS08
Dgr
|
H226
H341
H360FD
H331
H302
H314
H317
|
EUH071
|
inhalation: ATE = 2,7 mg/L (dampe)
oral: ATE = 404 mg/kg bw«
|
|
»607-745-00-6
|
glyoxylsyre …%
|
206-058-5
|
298-12-4
|
Eye Dam. 1
Skin Sens. 1B
|
H318
H317
|
GHS05
GHS07
Dgr
|
H318
H317
|
|
|
B«
|
»607-746-00-1
|
natrium-N-(hydroxymethyl)glycinat;
[formaldehyd frigivet fra natrium-N-(hydroxymethyl)glycinat]
|
274-357-8
|
70161-44-3
|
Carc. 1B
Muta. 2
Acute Tox. 4
Acute Tox. 4
STOT SE 3
Skin Irrit. 2
Eye Irrit. 2
Skin Sens. 1
|
H350
H341
H332
H302
H335
H315
H319
H317
|
GHS08
GHS07
Dgr
|
H350
H341
H332
H302
H335
H315
H319
H317
|
|
inhalation: ATE = 3 mg/L (støv eller tåge)
oral: ATE = 1100 mg/kg bw
|
8
9«
|
»611-181-00-6
|
kalium (oxido-NNO-azoxy)cyclohexan;
cyclohexylhydroxydiazen-1-oxid, kaliumsalt;
[K-HDO]
|
—
|
66603-10-9
|
Flam. Sol. 1
Acute Tox. 3
STOT RE 2
Skin Irrit. 2
Eye Dam. 1
Aquatic Chronic 2
|
H228
H301
H373 (lever)
H315
H318
H411
|
GHS02
GHS06
GHS08
GHS05
GHS09
Dgr
|
H228
H301
H373 (lever)
H315
H318
H411
|
|
oral: ATE = 136 mg/kg bw«
|
|
»612-294-00-3
|
mecetroniumetilsulfat;
N-ethyl-N,N-dimethylhexadecan-1-aminiumethylsulfat;
mecetroniumethylsulfat
[MES]
|
221-106-5
|
3006-10-8
|
Skin Corr. 1
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
|
H314
H318
H400
H410
|
GHS05
GHS09
Dgr
|
H314
H410
|
EUH071
|
M = 100
M = 1000«
|
|
»613-331-00-6
|
(2RS)-2-[4-(4-chlorphenoxy)-2-(trifluormethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol;
mefentrifluconazol
|
—
|
1417782-03-6
|
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
|
H317
H400
H410
|
GHS07
GHS09
Wng
|
H317
H410
|
|
M = 1
M = 1«
|
|
»613-332-00-1
|
oxathiapiprolin (ISO);
1-(4-{4-[5-(2,6-difluorphenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluormethyl)-1H-pyrazol-1-yl]ethanon
|
—
|
1003318-67-9
|
Aquatic Chronic 1
|
H410
|
GHS09
Wng
|
H410
|
|
M = 1«
|
|
»613-333-00-7
|
zinkpyrithion; (T-4)-bis[1-(hydroxy-.kappa.O)pyridin-2(1H)-thionato-.kappa.S]zink
|
236-671-3
|
13463-41-7
|
Repr. 1B
Acute Tox. 2
Acute Tox. 3
STOT RE 1
Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
|
H360D
H330
H301
H372
H318
H400
H410
|
GHS08
GHS06
GHS05
GHS09
Dgr
|
H360D
H330
H301
H372
H318
H410
|
|
inhalation: ATE = 0,14 mg/L (støv eller tåge)
oral: ATE = 221 mg/kg bw
M = 1000
M = 10«
|
|
»613-334-00-2
|
flurochloridon (ISO);
3-chlor-4-(chlormethyl)-1-[3-(trifluormethyl)phenyl]pyrrolidin-2-on
|
262-661-3
|
61213-25-0
|
Repr. 1B
Acute Tox. 4
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
|
H360FD
H302
H317
H400
H410
|
GHS08
GHS07
GHS09
Dgr
|
H360FD
H302
H317
H410
|
|
oral: ATE = 500 mg/kg bw
M = 100
M = 100«
|
|
»613-335-00-8
|
4,5-dichlor-2-octyl-2H-isothiazol-3-on; [DCOIT]
|
264-843-8
|
64359-81-5
|
Acute Tox. 2
Acute Tox. 4
Skin Corr. 1
Eye Dam. 1
Skin Sens. 1A
Aquatic Acute 1
Aquatic Chronic 1
|
H330
H302
H314
H318
H317
H400
H410
|
GHS06
GHS05
GHS09
Dgr
|
H330
H302
H314
H317
H410
|
EUH071
|
inhalation: ATE = 0,16 mg/L (støv eller tåge)
oral: ATE = 567 mg/kg bw
Skin Irrit. 2; H315: 0,025 % ≤ C < 5 %
Eye Irrit. 2; H319: 0,025 % ≤ C < 3 %
Skin Sens. 1A; H317: C ≥ 0,0015 %
M = 100
M = 100«
|
|
»613-336-00-3
|
2-methyl-1,2-benzothiazol-3(2H)-on;
[MBIT]
|
—
|
2527-66-4
|
Acute Tox. 4
Acute Tox. 3
Skin Corr. 1C
Eye Dam. 1
Skin Sens. 1A
Aquatic Acute 1
Aquatic Chronic 2
|
H312
H301
H314
H318
H317
H400
H411
|
GHS06
GHS05
GHS09
Dgr
|
H312
H301
H314
H317
H410
|
EUH071
|
dermal: ATE = 1100 mg/kg bw
oral: ATE = 175 mg/kg bw
Skin Sens. 1A; H317: C ≥ 0,0015 %
M = 1«
|
|
»616-228-00-4
|
3-(difluormethyl)-1-methyl-N-(3',4',5'-trifluorbiphenyl-2-yl)pyrazol-4-carboxamid;
fluxapyroxad
|
—
|
907204-31-3
|
Lact.
Aquatic Acute 1
Aquatic Chronic 1
|
H362
H400
H410
|
GHS09
Wng
|
H362
H410
|
|
M = 1
M = 1«
|
|
»616-230-00-5
|
N-(hydroxymethyl)acrylamid; methylolacrylamid; [NMA]
|
213-103-2
|
924-42-5
|
Carc. 1B
Muta. 1B
STOT RE 1
|
H350
H340
H372 (perifere nervesystem)
|
GHS08
Dgr
|
H350
H340
H372 (perifere nervesystem)«
|
|
|
|
»616-231-00-0
|
5-fluor-1,3-dimethyl-N-[2-(4-methylpentan-2-yl)phenyl]-1H-pyrazol-4-carboxamid; 2'-[(RS)-1,3-dimethylbutyl]-5-fluor-1,3-dimethylpyrazol-4-carboxanilid;
penflufen
|
—
|
494793-67-8
|
Carc. 2
Aquatic Acute 1
Aquatic Chronic 1
|
H351
H400
H410
|
GHS08
GHS09
Wng
|
H351
H410
|
|
M = 1
M = 1«
|
|
»616-232-00-6
|
iprovalicarb (ISO);
isopropyl [(2S)-3-methyl-1-{[1-(4-methylphenyl)ethyl]amino}-1-oxobutan-2-yl]carbamat
|
—
|
140923-17-7
|
Carc. 2
|
H351
|
GHS08
Wng
|
H351«
|
|
|
|
»616-233-00-1
|
silthiofam (ISO);
N-allyl-4,5-dimethyl-2-(trimethylsilyl)thiophen-3-carboxamid
|
—
|
175217-20-6
|
STOT RE 2
Aquatic Chronic 2
|
H373
H411
|
GHS08
GHS09
Wng
|
H373
H411«
|
|
|
|
»650-057-00-6
|
Margosaekstrakt [koldpresset olie af Azadirachta indica-frø uden skaller ekstraheret med superkritisk kuldioxid]
|
283-644-7
|
84696-25-3
|
Aquatic Chronic 3
|
H412
|
|
H412«
|
|
|
|